Back to Annual Meeting

Back to Annual Meeting

APHA Scientific Session and Event Listing

Salvatore Libretto, PhD¹, James Sexton, PhD¹, Jeffrey Hoffman, PhD¹, Y. Henry Wong, PhD¹, Susanna Nemes, PhD², Kelly Munly, MS¹, Paul Earley, MD, FASM³, Rachel Lefebvre, PhD⁴, and David Mee-Lee, MD⁵. (1) Public Health Research, Danya International, Inc., 8737 Colesville Road, Suite 1100, Silver Spring, MD 20910, 240-645-1094, slibretto@danya.com, (2) Social Solutions, International, Inc., 18303 Wickham Road, Olney, MD 20832, (3) Earley Associates, PC, 4015 South Cobb Drive, Suite 120, Smyra, GA 30080, (4) Clinical Research Consultant, 610 Shannon Avenue, Indialantic, FL 32903, (5) Mee-Lee Training and Consulting, 4228 Boxelder Place, Davis, CA 95616

Research points to high rates of co-occurring mental health disorders among individuals presenting for substance abuse treatment. The co-occurrence of mental health and substance use disorders presents particular challenges for screening and assessment. With funding from NIDA, Danya International is developing a screening system for substance abuse treatment settings designed to rapidly identify potential mental health disorders that commonly coexist with substance-related disorders. This innovative, user-friendly computer-based screening system will also assess client placement needs based on ASAM's Patient Placement Criteria. This brief version of the PPC-2R will assist clinicians in determining the level of care/service indicated for each client. The questions are grouped in a series of passes that determines in the first pass whether the patient needs some form of inpatient intensive treatment and in the second pass whether one of the residential treatment options would be more appropriate. The program will end as soon as a placement decision has been made, so it is optional whether all questions are administered. This method shortens the average administration time, and has the benefit of requiring less time from patients who are lower functioning. Because the different outpatient options are typically not available in all settings, pass three was redesigned to be more client- and situation-centered. Guidelines for discussion will be provided to the clinician at the end of pass two. This presentation will discuss steps taken to develop this system including pilot test results, expert feedback, and preliminary reliability and validity outcomes.

Learning Objectives: At the conclusion of the session, the participant (learner) in this session will be able to

• List the mental health disorders that most commonly co-occur with substance abuse.
• Recognize the factors that influence level of care/services indicated and patient placement decisions in substance abuse treatment.
• Describe the process involved in developing a mental health and patient placement screening instrument.

Keywords: Screening Instruments, Co-morbid

Presenting author's disclosure statement:

Not Answered